Verici Dx plc

("Verici Dx" or the "Company")

Distribution of Verici Dx shares by EKF Diagnostics Holdings plc

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes the announcement made by EKF Diagnostics Holdings PLC ("EKF") this morning (RNS 3845P), declaring the distribution of its Verici Dx Investment Shares to Relevant EKF Shareholders via a distribution in specie.

These shares comprise of 9,098,611 ordinary shares in Verici Dx of £0.001 each and are subject to a Lock-up Period of 365 days from transfer.

Full details can be seen in the EKF announcement here:

https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862

Capitalised terms in this announcement carry the same definitions as in the EKF announcement.

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.